Argenica Therapeutics

Updates

Home

New investors

Announcements

Lora

Why Argenica Therapeutics?

upload.jpg

Last Friday was a big day of media for Argenica Therapeutics in Brisbane, with a press conference held at the Princess Alexandra Hospital to announce the dosing of the first Queensland ischaemic stroke patient in the phase 2 clinical trial of ARG-007.

Dr Meghan Thomas made her media debut, alongside PA’s Staff Specialist Neurologist Dr Michael Devlin, who is the principal investigator for the trial at the hospital. He is one of several global leaders in stroke and emergency setting clinical trials who are assisting in running the trial.

The announcement was covered by 7 News, 9 News, 10 News First, ABC, The Courier Mail and online stories across the nation via AAP.

We look forward to further hospitals across the country being activated for dosing!